Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G1XCGD Autologous CD34+ Cell Gene Therapy in X-Linked CGD
2024-512790-27-00Phase 2Completed
- Sponsor
- Généthon
- Start
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tirzepatide in X-linked chronic granulomatous disease (X-CGD), sponsored by Généthon. Primary endpoints: Safety of G1XCGD autologous gene therapy and Restoration and stability of NADPH oxidase function in granulocytes. Started Jul 2024; status: completed.
02
Drugs
03
Conditions
X-linked chronic granulomatous disease (X-CGD)
Beyond the preview
Go deeper on 2024-512790-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512790-27-00.